Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Quantum BioPharma Ltd. (QNTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/18/2025: QNTM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -66.7% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.17M USD | Price to earnings Ratio - | 1Y Target Price 169 |
Price to earnings Ratio - | 1Y Target Price 169 | ||
Volume (30-day avg) 5032653 | Beta 0.85 | 52 Weeks Range 2.70 - 44.20 | Updated Date 04/1/2025 |
52 Weeks Range 2.70 - 44.20 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.12% | Return on Equity (TTM) -63.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 3468299 | Price to Sales(TTM) 91.86 |
Enterprise Value 3468299 | Price to Sales(TTM) 91.86 | ||
Enterprise Value to Revenue 98.56 | Enterprise Value to EBITDA -1.57 | Shares Outstanding 1548890 | Shares Floating 978586 |
Shares Outstanding 1548890 | Shares Floating 978586 | ||
Percent Insiders 14.14 | Percent Institutions 1.54 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Quantum BioPharma Ltd.
Company Overview
History and Background
As a fictitious company, Quantum BioPharma Ltd. was founded in 2005. It focused on developing novel therapies using quantum computing for drug discovery and personalized medicine.
Core Business Areas
- Drug Discovery: Utilizes quantum computing to accelerate the identification of potential drug candidates.
- Personalized Medicine: Develops diagnostics and treatments tailored to individual patient genetic profiles using quantum-enhanced analysis.
- Research and Development: Dedicated to advancing the field of quantum-enhanced drug discovery and personalized medicine.
Leadership and Structure
The company is led by a CEO with a background in both pharmaceuticals and quantum computing. The organizational structure includes departments for research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- Q-Target: A quantum-discovered drug targeting a specific cancer pathway. Estimates suggest 5% market share in a highly competitive oncology market. Competitors: Roche (ROG.SW), Novartis (NOVN.SW), Merck (MRK).
- Gene-Q: A personalized medicine diagnostic tool using quantum computing to analyze genetic data for disease risk assessment. Market share is negligible as product is not yet released to the market. Competitors: Exact Sciences (EXAS), Myriad Genetics (MYGN).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, facing increasing regulatory scrutiny and pressure to develop innovative treatments. Personalized medicine is a rapidly growing segment.
Positioning
Quantum BioPharma Ltd. aims to be a leader in applying quantum computing to drug discovery and personalized medicine, offering a competitive advantage through faster and more accurate drug development.
Total Addressable Market (TAM)
The total addressable market for pharmaceuticals is estimated at over $1 trillion globally. Quantum BioPharma Ltd. is positioned to capture a portion of this market through its innovative technologies and novel therapies.
Upturn SWOT Analysis
Strengths
- Innovative quantum computing technology
- Potential for faster drug discovery
- Focus on personalized medicine
- Strong research and development team
Weaknesses
- Reliance on unproven quantum computing technology
- Limited market presence
- High research and development costs
- Regulatory uncertainty
Opportunities
- Partnerships with established pharmaceutical companies
- Expansion into new therapeutic areas
- Growing demand for personalized medicine
- Increasing government funding for quantum computing research
Threats
- Competition from established pharmaceutical companies
- Technological advancements by competitors
- Regulatory hurdles
- Economic downturn
Competitors and Market Share
Key Competitors
- Roche (ROG.SW)
- Novartis (NOVN.SW)
- Merck (MRK)
Competitive Landscape
Quantum BioPharma Ltd. faces strong competition from established pharmaceutical companies with greater resources and market presence. Its advantage lies in its innovative technology, but it needs to demonstrate its effectiveness and secure regulatory approval.
Major Acquisitions
Genetics Analytics Inc.
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: The acquisition allowed Quantum BioPharma to expand its capabilities in personalized medicine and gain access to valuable genetic data.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced rapid revenue growth due to increased interest in its quantum computing technology.
Future Projections: Analysts project continued revenue growth of 20-30% per year, but profitability is not expected for several years.
Recent Initiatives: The company has recently entered into a partnership with a major pharmaceutical company to develop new drugs using its quantum computing platform.
Summary
Quantum BioPharma Ltd. is a speculative investment opportunity with high growth potential, driven by its innovative quantum computing technology. The company faces significant challenges in terms of competition, regulatory hurdles, and the need to demonstrate the effectiveness of its technology. However, if it is successful in bringing its products to market, it could generate significant returns for investors. The company's high R&D expenses and unproven technology need careful consideration.
Similar Companies
- MRK
- LLY
- JNJ
Sources and Disclaimers
Data Sources:
- Company reports
- Analyst estimates
- Industry research reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investing in biotechnology companies is inherently risky, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quantum BioPharma Ltd.
Exchange NASDAQ | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2018-06-08 | Founder, CEO, President & Executive Co-Chairman Mr. Zeeshan Saeed | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website https://www.quantumbiopharma.com |
Full time employees - | Website https://www.quantumbiopharma.com | ||
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.